Prothena’s partnered programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies; programs that target tau (PRX005), TDP-43, and PRX019 in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases; and a partnership with Novo Nordisk for NNC6019/PRX004 for the potential treatment of ATTR amyloidosis. Prothena’s wholly-owned programs include a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aβ (Amyloid beta) and PRX123, the company’s dual Aβ-tau vaccine.